Bharat Biotech partners with Alopexx to develop anti-microbial vaccine

Q: How long will it take to read this news story?

The story "Bharat Biotech partners with Alopexx to develop anti-microbial vaccine" has 299 words across 10 sentences, which will take approximately 2 - 3 minutes for the average person to read.

Q: Which news outlet covered this story?

The story "Bharat Biotech partners with Alopexx to develop anti-microbial vaccine" was covered 5 hours ago by Business Standard, a news publisher based in India.

Q: How trustworthy is 'Business Standard' news outlet?

Business Standard is a fully independent (privately-owned) news outlet established in 1975 that covers mostly business and finance news. The outlet is headquartered in India and publishes an average of 321 news stories per day. It's most recent story was published 2 hours ago.

Q: What do people currently think of this news story?

The sentiment for this story is currently Neutral, indicating that people are not responding positively or negatively to this news.

Q: How do I report this news for inaccuracy?

You can report an inaccurate news publication to us via our contact page. Please also include the news #ID number and the URL to this story.<ul><li>News ID: #22457064</li><li>URL: https://beamstart.com/news/bharat-biotech-partners-with-alopexx-1726045417923</li></ul>

Business Standard Logo Business Standard 5h ago

Bharat Biotech partners with Alopexx to develop anti-microbial vaccine - Business Standard

Quick Summary:

Bharat Biotech on Wednesday announced a collaboration with Alopexx Inc for development and commercialisation of the latter's broad-spectrum anti-microbial vaccine in India and other low income countries.

As part of the collaboration, the companies will co-develop and commercialise the vaccine -- AV0328, in India and other licensed territories, Bharat Biotech said in a statement.

This collaboration aligns with our mission to provide safe, affordable, and high-quality vaccines to combat infectious diseases globally," Bharat Biotech Executive Chairman Krishna Ella said.